Drug Trial Radar · NCT07400965
Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis
Last checked: Nov 19, 2026Latest source record: Feb 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
250
Planned (sponsor's estimate)
Start
Dec 5, 2025
Primary completion
Sep 2026
Study completion Nov 2026
Sponsor
- Lead sponsor
- Glaukos CorporationIndustry
- Sponsor type
- Industry
- First posted
- Feb 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-masked, placebo-controlled, dose-ranging, parallel-group, multi-center study designed to evaluate the safety and efficacy of GLK-321 in patients with Demodex blepharitis.
Conditions
- Demodex Blepharitis
Interventions
GLK-321 low dose BIDDrug
Twice daily administration of low dose GLK-321 to both eyes
GLK-321 mid dose BIDDrug
Twice daily administration of mid dose GLK-321 to both eyes
GLK-321 high dose BIDDrug
Twice daily administration of high dose GLK-321 to both eyes
GLK-321 high dose QDDrug
Once daily administration of high dose GLK-321 to both eyes
Placebo BIDDrug
Twice daily administration of placebo to both eyes
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of study eyes with elimination of collarettesTime frame: 6 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Glaukos Clinical Study Site
Newport Beach, California · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.